Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B - PubMed (original) (raw)
Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B
Chad A Knoderer et al. J Pediatr Pharmacol Ther. 2011 Apr.
Abstract
Objective: After transitioning our front-line amphotericin product to the liposomal formulation, we observed an increased incidence of hyperphosphatemia. We aimed to determine the incidence of hyperphosphatemia in children with oncologic disorders receiving an amphotericin B product and to establish whether the incidence varies depending on amphotericin formulation.
Methods: This retrospective review of the medical record was conducted at a tertiary, free standing children's hospital. Pharmacy data revealed 159 patients receiving an amphotericin product between November 2006 and December 2008. Doses of amphotericin, serum phosphorous, calcium and creatinine concentrations were recorded at daily time points during the 10 days following both initiation and discontinuation of amphotericin. Administration of phosphate binders and total parenteral nutrition was noted. The incidence of hyperphosphatemia, defined as a serum value greater than the age-adjusted upper limit of normal, was compared among the amphotericin groups.
Results: One hundred thirty-nine amphotericin recipients had a serum phosphorus measurement during amphotericin therapy. Final analysis included 117 children, of which 64 (55%) were oncology patients. Deoxycholate (mean maximum dose 1 mg/kg), lipid complex (mean maximum dose 4.8 mg/kg) and liposomal amphotericin (mean maximum dose 4.9 mg/kg) were used in 24 (20.5%), 37 (31.6%) and 56 (47.9%) of all patients, respectively. Hyperphosphatemia developed in 27% (32/117) of all patients, and in 33% (21/64) of oncology patients. Similar to within all recipients, among oncology patients, 45% (n=18) of liposomal recipients demonstrated hyperphosphatemia compared to 13% of those receiving lipid complex (n=3, p=0.007). No oncology patient received deoxycholate.
Conclusion: Nearly 45% of children with oncologic disorders receiving liposomal amphotericin developed hyperphosphatemia. The incidence is significantly greater for the liposomal formulation than either of the other amphotericin formulations.
Similar articles
- Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.
Bohm NM, Hoover KC, Wahlquist AE, Zhu Y, Velez JC. Bohm NM, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):6816-23. doi: 10.1128/AAC.01306-15. Epub 2015 Aug 17. Antimicrob Agents Chemother. 2015. PMID: 26282423 Free PMC article. - Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD, Lyseng-Williamson KA, Scott LJ. Moen MD, et al. Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Drugs. 2009. PMID: 19275278 Review. - Pseudohyperphosphatemia associated with high-dose liposomal and lipid complex amphotericin B when tested with Synchron LX 20 (Beckman/Coulter) phosphorous assay.
Shiu JR, Forgie SE, Pinsk M, Romanick M. Shiu JR, et al. J Pediatr Hematol Oncol. 2012 May;34(4):e155-7. doi: 10.1097/MPH.0b013e3182300254. J Pediatr Hematol Oncol. 2012. PMID: 22146534 - Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA, Owais M. Khan MA, et al. J Antimicrob Chemother. 2006 Jul;58(1):125-32. doi: 10.1093/jac/dkl177. Epub 2006 May 18. J Antimicrob Chemother. 2006. PMID: 16709592 - Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ, Drew RH, Perfect JR. Gibbs WJ, et al. Expert Rev Anti Infect Ther. 2005 Apr;3(2):167-81. doi: 10.1586/14787210.3.2.167. Expert Rev Anti Infect Ther. 2005. PMID: 15918775 Review.
Cited by
- Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.
Bohm NM, Hoover KC, Wahlquist AE, Zhu Y, Velez JC. Bohm NM, et al. Antimicrob Agents Chemother. 2015 Nov;59(11):6816-23. doi: 10.1128/AAC.01306-15. Epub 2015 Aug 17. Antimicrob Agents Chemother. 2015. PMID: 26282423 Free PMC article.
References
- Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist Updat. 2005;8(4):235–245. - PubMed
- Filioti I, Iosifidis E, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother. 2008;9(18):3179–3196. - PubMed
- Jain A, Butani L. Severe hyperphosphatemia resulting from high-dose liposomal amphotericin in a child with leukemia. J Pediatr Hematol Oncol. 2003;25(4):324–326. - PubMed
- Sutherland SM, Hong DK, Balagtas J, et al. Liposomal amphotericin B associated with severe hyperphosphatemia. Pediatr Infect Dis J. 2008;27(1):77–79. - PubMed
- Mendoza D, Connors S, Lane C, et al. Liposomal amphotericin B as a cause of pseudohyperphosphatemia. Clin Infect Dis. 2008;46(4):645–646. - PubMed
LinkOut - more resources
Full Text Sources